Compare Bristol-Myers Squibb Co (BMY) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs AT&T Inc. — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while AT&T Inc. trades at $21.46 (market cap $147.86B). The key difference: AT&T Inc. is the larger of the two by market cap, and AT&T Inc. pays the higher dividend (5.22%). Which is the better fit depends on your goals.
| BMY | T | |
|---|---|---|
Market Cap | $116.30B | $147.86B |
Sector | Health | Media |
52-Week High | $62.37 | $29.62 |
52-Week Low | $42.60 | $20.49 |
Enterprise Value | $152.24B | $293.21B |
Dividend Yield | 4.42% | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
AT&T (T) trades at $21.57, up 2.06% today but near 52-week lows amid Starlink competition fears. The stock shows bearish technical signals with RSI at 97.16 suggesting overbought conditions. Fundamentally, T maintains strong profitability with a 16.94% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights SpaceX's satellite-to-phone ambitions creating sector-wide pressure, though AT&T continues innovation with 5G drone detection trials.
Despite near-term headwinds, AT&T presents value with a 5.3% dividend yield and low P/E of 7.26. The consensus price target of $26.43 implies 22.6% upside potential. Primary risks include Starlink disruption and telecom sector volatility, but strong cash flow generation and analyst buy ratings (41%) support a constructive long-term outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
